New study tests local injections for stubborn skin lesions

NCT ID NCT07261072

First seen Jan 02, 2026 · Last updated May 17, 2026 · Updated 21 times

Summary

This study tests if injecting secukinumab directly into skin lesions works better and is safer than standard shots under the skin for people with mild, localized hidradenitis suppurativa (HS). About 30 adults with HS that hasn't responded to usual treatments will receive either topical or subcutaneous injections. The goal is to see if local delivery improves response and reduces side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, Jiangsu 210042

    Nanjing, Jiangsu, 210042, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.